ORIP-1001

N/A

Report date: 2025/10/20 14:18:34
NME

Base Information

Drug NameORIP-1001
Drug Alias NameORIP-1001
ClassificationSmall molecules
Mechanisms of ActionReceptor-interacting serine/threonine-protein kinase 1 inhibitors
TargetsReceptor-interacting serine/threonine-protein kinase 1
Therapy Area/IndicationsLymphohistiocytosis, Hemophagocytic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesChongqing Pharscin Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChongqing Pharscin Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphohistiocytosis, Hemophagocytic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A